Porrata LF, Markovic SN

Idioma: Ingles.
Referencias bibliográficas: 32
Paginas: 108-113
Archivo PDF: 436.20 Kb.

RESUMEN

La ventaja terapéutica de los trasplantes alogénicos de células madre se atribuye al efecto contra tumor que producen las células efectoras de la inmunidad del donador para erradicar las células tumorales. Sin embargo, la respuesta inmunitaria que producen las células efectoras de la inmunidad del donador no es específica, lo que no sólo crea el efecto de injerto contra tumor, sino también efectos perjudiciales de la enfermedad de injerto contra anfitrión. Los estudios recientes reportan que la infusión de linfocitos "espectadores" de autoinjerto de células madre se correlaciona con la recuperación de linfocitos y los resultados clínicos de pacientes en proceso de implante autólogo de células madre; algo parecido al efecto de injerto contra tumor visto en el trasplante alogénico de células madre, sin los efectos negativos de injerto contra anfitrión. La evidencia de que las células efectoras de la inmunidad del huésped recogidas al mismo tiempo que las células madre pueden mejorar los resultados clínicos después del implante autólogo de células madre, sugiere que el autoinjerto puede considerarse no sólo una estrategia terapéutica para recobrar la función de la médula ósea después de aplicar altas dosis de quimioterapia, sino también como una intervención de inmunoterapia adoptiva capaz de erradicar las células tumorales en pacientes con cáncer. En este artículo se revisa la manera de mejorar la recolección de células efectoras de la inmunidad del anfitrión, las diferentes células efectoras de la inmunidad recolectadas e infundidas desde autoinjerto de células madre y su asociación con el resultado clínico después de implante autólogo de células madre.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Appelbaum FR. Hematopoietic stem cell transplantation as immunotherapy. Nature 2001;411:385-389.

2. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med 2004;4:78-85.

3. Porrata LF. Clinical evidence of autologous graft-versus-tumor effect. American Journal of Immunology 2009;5(1):1-7.

4. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef INM, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplantation 2004;33:291-298 doi:10.1038/ sj.bmt.1704355.

5. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085-1092 doi:10.1038/sj.leu.2403341.

6. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma and non-Hodgkin’s lymphoma. Blood 2001;16:579-585.

7. Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002;16:1311-1318.

8. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous hematopoietic stem cell transplantation is associated with better survival in Hodgkin’s disease. British J. Haematol 2002;117:629-633.

9. Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clinical Cancer Research 2005;11(3):1210-1218.

10. Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplantation 2006;37(9):865-871.

11. Porrata LF, Ingle JN, Litzow MR, Geyer SM, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplantation 2001;28:865-871.

12. Ferrandina G, Pierelli L, Perillo A et al. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clinical Cancer Research 2003;9(10):195-200.

13. Boulassel MR, Herr AL, deB Edwards MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology 2006;11(3):165-170.

14. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplantation 2006;37(11):1037-1042.

15. Nieto Y, Shapall EJ, McNiece IK, et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with autologous hematopoietic peripheral progenitor cell transplant. Clinical Cancer Research 2004;10(15):5076-5086.

16. Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplantation 2004;34(10):43-49.

17. Gordan LN, Surge MW, Lynch JW, Williams KD, Khan SA, Moreb JS. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplantation 2003;31(11):1009-1013.

18. Porrata, LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biology of Blood & Marrow Transplantation 2008;14(7):807-816.

19. Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplantation 2004;33:291-298.

20. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085-1092.

21. Hiwase DK, Hiwase S, Baily M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biology Blood Marrow Transplant 2008;14:116-124.

22. Schmidmaier R, Oversohl N, Schnabel B, Straka C, Emmerich B. Helper T cells (CD3+/CD4+) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol 2008;30:240-243.

23. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771-3779.

24. Atta EH, de Azevedo AM, Maiolino A, Coelho CJBP, Sarcinelli SMP, Maximo CdA, Marra VLN. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation. American Journal of Hematology 2009;84:21-28.

25. Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous natural killer cells correlate with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44: 997-1000.

26. Dean R, Masci P, Pohlman B, Andresen S, Sera􀂿no S, Sobecks R, Kuczkowski E, Curtis J, Maciejewski J, Rybicki L, Kalaycio M, His E, Theil K, Bolwell BJ. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post-transplant recovery predict survival. Bone Marrow Transplant 2005;36: 1049-1052.

27. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy 2008; 10(5): 507-517 doi: 10.1080/14653240802165665.

28. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Buyer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy expansion of immune effectors within the stem-cell graft and post-stem cell infusion. J Clin Oncol 2001;19:634-644.

29. Fehniger TA, Caligiuri MA. Interleukin-15: biology and relevance to human disease. Blood 2001;97:14-32.

30. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Pusnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.

31. Holtan SG, Porrata LF, Micallef IN, et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma myeloma 2007;7:315-318.

32. Katipamula R, Porrata LF, Gastineau DA, Markovic SN, Moore SB, Greiner C, Burgstaler EA, Padley DJ, Winters JL. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplantation 2006;37(9):811-817 doi: 10.1038/sj.bmt.1705338.